Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region & Competition, 2020-2030F

Description

Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 21.06 Billion
Market Size 2030	USD 30.60 Billion
CAGR 2025-2030	6.57%
Fastest Growing Segment	Oral
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches

A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.

Key Market Players

Glanbia Plc
Pfizer Inc.
Bayer AG
Amway Corp.
GlaxoSmithKline plc.
Good Health New Zealand
The Nature's Bounty Co.
NOW Foods
Abbott
Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

TNF Alpha Inhibitors
PDE4 Inhibitors
Interleukin Inhibitors
Others

Psoriasis Drugs Market, By Route of Administration:

Oral
Parenteral
Topical

Psoriasis Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Route of Administrations
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
- 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type of Treatment
- 6.2.2. By Mechanism of Action
- 6.2.3. By Route of Administration
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Psoriasis Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type of Treatment
    - 6.3.1.2.2. By Mechanism of Action
    - 6.3.1.2.3. By Route of Administration
- 6.3.2. Canada Psoriasis Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type of Treatment
    - 6.3.2.2.2. By Mechanism of Action
    - 6.3.2.2.3. By Route of Administration
- 6.3.3. Mexico Psoriasis Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type of Treatment
    - 6.3.3.2.2. By Mechanism of Action
    - 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type of Treatment
- 7.2.2. By Mechanism of Action
- 7.2.3. By Route of Administration
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Psoriasis Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type of Treatment
    - 7.3.1.2.2. By Mechanism of Action
    - 7.3.1.2.3. By Route of Administration
- 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type of Treatment
    - 7.3.2.2.2. By Mechanism of Action
    - 7.3.2.2.3. By Route of Administration
- 7.3.3. Italy Psoriasis Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Type of Treatment
    - 7.3.3.2.2. By Mechanism of Action
    - 7.3.3.2.3. By Route of Administration
- 7.3.4. France Psoriasis Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type of Treatment
    - 7.3.4.2.2. By Mechanism of Action
    - 7.3.4.2.3. By Route of Administration
- 7.3.5. Spain Psoriasis Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type of Treatment
    - 7.3.5.2.2. By Mechanism of Action
    - 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type of Treatment
- 8.2.2. By Mechanism of Action
- 8.2.3. By Route of Administration
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Psoriasis Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type of Treatment
    - 8.3.1.2.2. By Mechanism of Action
    - 8.3.1.2.3. By Route of Administration
- 8.3.2. India Psoriasis Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type of Treatment
    - 8.3.2.2.2. By Mechanism of Action
    - 8.3.2.2.3. By Route of Administration
- 8.3.3. Japan Psoriasis Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type of Treatment
    - 8.3.3.2.2. By Mechanism of Action
    - 8.3.3.2.3. By Route of Administration
- 8.3.4. South Korea Psoriasis Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type of Treatment
    - 8.3.4.2.2. By Mechanism of Action
    - 8.3.4.2.3. By Route of Administration
- 8.3.5. Australia Psoriasis Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type of Treatment
    - 8.3.5.2.2. By Mechanism of Action
    - 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type of Treatment
- 9.2.2. By Mechanism of Action
- 9.2.3. By Route of Administration
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Psoriasis Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type of Treatment
    - 9.3.1.2.2. By Mechanism of Action
    - 9.3.1.2.3. By Route of Administration
- 9.3.2. Argentina Psoriasis Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type of Treatment
    - 9.3.2.2.2. By Mechanism of Action
    - 9.3.2.2.3. By Route of Administration
- 9.3.3. Colombia Psoriasis Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type of Treatment
    - 9.3.3.2.2. By Mechanism of Action
    - 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type of Treatment
- 10.2.2. By Mechanism of Action
- 10.2.3. By Route of Administration
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Psoriasis Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type of Treatment
    - 10.3.1.2.2. By Mechanism of Action
    - 10.3.1.2.3. By Route of Administration
- 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type of Treatment
    - 10.3.2.2.2. By Mechanism of Action
    - 10.3.2.2.3. By Route of Administration
- 10.3.3. UAE Psoriasis Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type of Treatment
    - 10.3.3.2.2. By Mechanism of Action
    - 10.3.3.2.3. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

14.1. Glanbia Plc
- 14.1.1. Business Overview
- 14.1.2. Mechanism of Action Offerings
- 14.1.3. Recent Developments
- 14.1.4. Key Personnel
- 14.1.5. SWOT Analysis
14.2. Pfizer Inc.
14.3. Bayer AG
14.4. Amway Corp.
14.5. GlaxoSmithKline plc.
14.6. Good Health New Zealand
14.7. The Nature's Bounty Co.
14.8. NOW Foods
14.9. Abbott
14.10. Herbalife Nutrition